The Effects of Scheduled Smoking Reduction and Precessation Nicotine Replacement Therapy on Smoking Cessation: Randomized Controlled Trial With Compliance.
compliance
gradual reduction
mobile phone
nicotine replacement therapy
scheduled smoking
smoking cessation
Journal
JMIR formative research
ISSN: 2561-326X
Titre abrégé: JMIR Form Res
Pays: Canada
ID NLM: 101726394
Informations de publication
Date de publication:
20 Jun 2023
20 Jun 2023
Historique:
received:
11
05
2022
accepted:
30
04
2023
revised:
04
04
2023
medline:
20
6
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
epublish
Résumé
Smoking remains a major public health problem, and it is important to provide a variety of efficacious and appealing options to encourage smokers to quit smoking. Scheduled smoking is a method of gradual reduction, preparing smokers to quit by systematically reducing cigarette consumption according to a predetermined schedule that increases the time between cigarette consumption. Gradual reduction may be preferred to abrupt quitting, but the efficacy of this cessation approach is unclear. This study aims, first, to evaluate the overall effectiveness of scheduled smoking alone, or in combination with precessation nicotine replacement therapy (NRT), versus standard NRT starting on the quit date with no prior smoking reduction and, second, to evaluate the impact of schedule compliance on the effectiveness of the intervention. A total of 916 participants recruited from the Houston metropolitan area were randomly assigned to 1 of the following 3 groups: scheduled smoking plus a precessation nicotine patch (n=306, 33.4%), scheduled smoking only with no precessation patch (n=309, 33.7%), and enhanced usual care (n=301, 32.9%) control. The primary abstinence outcomes were carbon monoxide-verified, self-reported, 7-day point prevalence abstinence at 2 and 4 weeks after the quit date. Unadjusted and adjusted logistic regression analyses were performed to evaluate the intervention effect. Scheduled smoking was implemented using a handheld device for 3 weeks before quitting. This trial was not registered because data collection began before July 1, 2005. Results for the first aim showed no overall differences in abstinence among the 3 groups in both the unadjusted and adjusted models. However, the results for the second aim showed a clear effect on abstinence by schedule compliance at 2 and 4 weeks and 6 months after quitting (odds ratio [OR] 2.01, 95% CI 1.31-3.07), 4 weeks (OR 1.58, 95% CI 1.05-2.38), and 6 months (OR 1.68, 95% CI 1.04-2.64), with the differences at 2 and 4 weeks after quitting being the most robust. We also found that scheduled smoking was related to a reduction in nicotine withdrawal, negative affect, and craving when compared with the controls. Scheduled smoking, when combined with precessation use of NRT, can result in significantly higher abstinence rates than usual care (abrupt quitting with NRT), particularly in the early postquit phase (2 and 4 weeks after cessation) when smokers are compliant with the procedure. Scheduled smoking also produced a better overall quitting experience by reducing symptoms of nicotine withdrawal and craving, in comparison with usual care, which could encourage future quit attempts. Studies in this area should focus on the use of counseling or other methods to improve adherence.
Sections du résumé
BACKGROUND
BACKGROUND
Smoking remains a major public health problem, and it is important to provide a variety of efficacious and appealing options to encourage smokers to quit smoking. Scheduled smoking is a method of gradual reduction, preparing smokers to quit by systematically reducing cigarette consumption according to a predetermined schedule that increases the time between cigarette consumption. Gradual reduction may be preferred to abrupt quitting, but the efficacy of this cessation approach is unclear.
OBJECTIVE
OBJECTIVE
This study aims, first, to evaluate the overall effectiveness of scheduled smoking alone, or in combination with precessation nicotine replacement therapy (NRT), versus standard NRT starting on the quit date with no prior smoking reduction and, second, to evaluate the impact of schedule compliance on the effectiveness of the intervention.
METHODS
METHODS
A total of 916 participants recruited from the Houston metropolitan area were randomly assigned to 1 of the following 3 groups: scheduled smoking plus a precessation nicotine patch (n=306, 33.4%), scheduled smoking only with no precessation patch (n=309, 33.7%), and enhanced usual care (n=301, 32.9%) control. The primary abstinence outcomes were carbon monoxide-verified, self-reported, 7-day point prevalence abstinence at 2 and 4 weeks after the quit date. Unadjusted and adjusted logistic regression analyses were performed to evaluate the intervention effect. Scheduled smoking was implemented using a handheld device for 3 weeks before quitting. This trial was not registered because data collection began before July 1, 2005.
RESULTS
RESULTS
Results for the first aim showed no overall differences in abstinence among the 3 groups in both the unadjusted and adjusted models. However, the results for the second aim showed a clear effect on abstinence by schedule compliance at 2 and 4 weeks and 6 months after quitting (odds ratio [OR] 2.01, 95% CI 1.31-3.07), 4 weeks (OR 1.58, 95% CI 1.05-2.38), and 6 months (OR 1.68, 95% CI 1.04-2.64), with the differences at 2 and 4 weeks after quitting being the most robust. We also found that scheduled smoking was related to a reduction in nicotine withdrawal, negative affect, and craving when compared with the controls.
CONCLUSIONS
CONCLUSIONS
Scheduled smoking, when combined with precessation use of NRT, can result in significantly higher abstinence rates than usual care (abrupt quitting with NRT), particularly in the early postquit phase (2 and 4 weeks after cessation) when smokers are compliant with the procedure. Scheduled smoking also produced a better overall quitting experience by reducing symptoms of nicotine withdrawal and craving, in comparison with usual care, which could encourage future quit attempts. Studies in this area should focus on the use of counseling or other methods to improve adherence.
Identifiants
pubmed: 37338956
pii: v7i1e39487
doi: 10.2196/39487
pmc: PMC10337448
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e39487Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA011822
Pays : United States
Informations de copyright
©Paul M Cinciripini, Jennifer A Minnix, Jason D Robinson, George Kypriotakis, Yong Cui, Janice A Blalock, Cho Y Lam, David W Wetter. Originally published in JMIR Formative Research (https://formative.jmir.org), 20.06.2023.
Références
Addict Behav. 1994 Jan-Feb;19(1):13-22
pubmed: 8197889
Nicotine Tob Res. 2006 Aug;8(4):555-64
pubmed: 16920653
Am J Epidemiol. 1984 Jun;119(6):997-1004
pubmed: 6731436
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Thorax. 2000 Dec;55(12):987-99
pubmed: 11083883
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000146
pubmed: 18253970
Epidemiology. 2006 Jul;17(4):360-72
pubmed: 16755261
Mol Med. 2010 Jul-Aug;16(7-8):247-53
pubmed: 20379614
Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
Nicotine Tob Res. 2007 Jun;9(6):671-5
pubmed: 17558824
JAMA. 2015 Feb 17;313(7):687-94
pubmed: 25688780
Addiction. 2018 Apr;113(4):759-763
pubmed: 29139190
Nicotine Tob Res. 2009 Sep;11(9):1067-75
pubmed: 19567826
Implement Sci. 2013 Apr 04;8:40
pubmed: 23557119
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Addiction. 2020 Oct;115(10):1797-1799
pubmed: 31845439
J Subst Abuse Treat. 2017 Jun;77:141-149
pubmed: 28245946
Drugs. 2013 Apr;73(5):407-26
pubmed: 23572407
Addict Behav. 1997 Nov-Dec;22(6):759-67
pubmed: 9426793
J Consult Clin Psychol. 1996 Aug;64(4):791-8
pubmed: 8803370
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Cochrane Database Syst Rev. 2019 Sep 30;9:CD013183
pubmed: 31565800
BMJ Open. 2016 Jun 09;6(6):e011045
pubmed: 27288378
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013-1019
pubmed: 31725711
Cochrane Database Syst Rev. 2018 May 31;5:CD000146
pubmed: 29852054
Am J Epidemiol. 2009 Feb 1;169(3):273-84
pubmed: 19033525
J Consult Clin Psychol. 1988 Feb;56(1):104-10
pubmed: 3346434
Nicotine Tob Res. 2007 Aug;9(8):801-10
pubmed: 17654293
Br J Addict. 1989 Jun;84(6):591-8
pubmed: 2752191
Tob Control. 1997 Winter;6(4):306-10
pubmed: 9583628
J Consult Clin Psychol. 1995 Jun;63(3):388-99
pubmed: 7608351
Arch Public Health. 2021 Mar 4;79(1):26
pubmed: 33663575
Nicotine Tob Res. 2007 Nov;9(11):1177-82
pubmed: 17978992
Addiction. 2018 Apr 21;:
pubmed: 29679432
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Drug Alcohol Depend. 2013 Feb 1;128(1-2):171-4
pubmed: 22939878
Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308
pubmed: 30997928
Nicotine Tob Res. 2013 Oct;15(10):1773-6
pubmed: 23569007
Addiction. 2004 Jan;99(1):29-38
pubmed: 14678060
Am J Prev Med. 2013 Dec;45(6):732-6
pubmed: 24237915
MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5
pubmed: 12186222
BMJ. 2009 Apr 02;338:b1024
pubmed: 19342408
Nicotine Tob Res. 2016 Oct;18(10):1944-1951
pubmed: 27185903
J Clin Psychopharmacol. 2002 Oct;22(5):487-95
pubmed: 12352272
Exp Clin Psychopharmacol. 1999 Nov;7(4):354-61
pubmed: 10609970
JAMA Psychiatry. 2013 May;70(5):522-33
pubmed: 23536105
Addiction. 2003 Oct;98(10):1395-402
pubmed: 14519176
Addiction. 2014 Jan;109(1):35-43
pubmed: 23919621
Cochrane Database Syst Rev. 2021 Jan 4;1:CD013229
pubmed: 33411338
BMC Public Health. 2017 Feb 17;17(1):210
pubmed: 28212652
J Consult Clin Psychol. 1981 Oct;49(5):648-58
pubmed: 7287974
Tob Induc Dis. 2019 Feb 13;17:09
pubmed: 31582921
Multivariate Behav Res. 1998 Oct 1;33(4):545-71
pubmed: 26753828
Addiction. 2007 Jul;102(7):1158-63
pubmed: 17567405
J Consult Clin Psychol. 1996 Apr;64(2):314-23
pubmed: 8871416
Psychopharmacology (Berl). 2001 May;155(2):115-22
pubmed: 11400998
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):397-405
pubmed: 35298455
Clin Trials. 2014 Feb;11(1):28-37
pubmed: 24096636
Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146
pubmed: 23152200
Health Psychol. 2014 Jul;33(7):737-47
pubmed: 23895203
Nicotine Tob Res. 2003 Apr;5(2):155-62
pubmed: 12745487
Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286
pubmed: 27009521
Clin Pharmacol Ther. 2005 Dec;78(6):689-96
pubmed: 16338284
Ann Intern Med. 2016 May 3;164(9):585-92
pubmed: 26975007